Launch of Flivas™ (naftopidil) in Korea

January 10, 2012
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma’s licensing partner, Dong-A Pharmaceutical Co., Ltd. (Dong-A), has launched the sale of Flivas™ (naftopidil) in Korea as an agent for the treatment of benign prostatic hyperplasia (BPH) on January 2, 2012.

Asahi Kasei Pharma and Dong-A concluded a license agreement in April 2009, granting Dong-A exclusive rights for the development and sale of Flivas™ in Korea. Dong-A obtained approval from the Korea Food and Drug Administration (KFDA) as an agent for the treatment of BPH in April 2011.

BPH is a condition in which an enlarged prostate gland causes urinary symptoms such as discomfort, incontinence, incomplete voiding, and nocturia. Naftopidil is an α1-blocker that suppresses the constriction of smooth muscle in the prostate gland and in the urethra, alleviating the discomfort and other symptoms of BPH.

Flivas™ has played an important role in improving the quality of life for many patients in Japan. As the population ages, Flivas™ will be an increasingly vital therapy for a growing number of patients. The partnership with Dong-A, which has a wealth of experience in the field of urology, will facilitate the rapid establishment of a major presence of Flivas™ in the vital Korean market.

Product outline

Product name: Flivas™
Generic name: Naftopidil
Dosage and form: 25 mg, 50 mg, and 75 mg tablet
Indication: Dysuria associated with benign prostatic hyperplasia (BPH)
Price: 375 won (25 mg), 600 won (50 mg), 733 won (75 mg)

Corporate profile of Dong-A Pharmaceutical Co., Ltd.

President: Won-Bae Kim
Head office: Seoul, Korea
Paid-in capital: 55.7 billion won (as of Dec. 31, 2010)
Business line: Production and sale of pharmaceuticals
Net sales: 846.8 billion won (year ended Dec. 31, 2010)
Employees: 2,282


Adobe Readeris required to view these PDF files.

page top